Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Getinge AB
  6. News
  7. Summary
    GETI B   SE0000202624

GETINGE AB

(GETI B)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 06/18 11:29:43 am
315.7 SEK   +1.12%
06/11GETINGEá : The future of health care is connected
PU
06/10Getinge Launches Torin AI Software In US
MT
06/10GETINGEá : New Torin Artificial Intelligence Solution Improves Hospital Efficiency
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Getinge : completes acquisition of Applikon Biotechnology B.V.

01/03/2020 | 01:31pm EDT

Getinge has today completed the previously announced acquisition of 100% of the shares in Applikon Biotechnology B.V. from Applikon Biotechnology Holding B.V..

On December 20, 2019, Getinge announced an agreement to acquire Applikon Biotechnology B.V., a leading company in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as well as enzymes and bio-plastics for industrial biotechnology.

All conditions for the transaction and closing have now been fulfilled. The transaction was completed today with effect as from January 1[st], 2020. As previously announced, Getinge have paid approximately SEK 840 M (EUR 80 M) in cash on closing for 100 % of the shares. In addition, a maximum earn out of approximately SEK 630 M (EUR 60 M) can be paid out in 2021-2022 if agreed earnings performance is achieved in 2020-2021. The acquisition will be financed through debt and the net debt to EBITDA ratio is expected to be impacted by 0.2x at closing of deal. Getinge expects no material integration costs in 2020-2021.

Long-term, Applikon Biotechnology B.V. is expected to bring a material contribution to Getinge's Life Science business area in terms of net sales and EBITA. Getinge's Life Science business performed SEK 2.3 B in net sales and SEK 293 M in EBITA Q4 2018-Q3 2019. For Getinge, the acquisition is not expected to have a material impact on operating profit and earnings per share as of 2020. The acquisition broadens Getinge's position further within solutions for efficient, safe and contamination-free research and production processes in the biopharma segment.

For more information about Applikon Biotechnology B.V.: www.applikon-biotechnology.com

To read the press release from December 20, 2019, click here (https://www.getinge.com/int/about-us/press/news/press-releases/2019/6895-Getinge-to-acquire-Applikon-Biotechnology-B.V.-a-leading/) or visit www.getinge.com.

Media contact:

Lars Mattson, Head of Investor Relations
Tel: +46 (0)10 335 0043
Email: lars.mattsson@getinge.com

Jeanette Hedén Carlsson, EVP Communication & Academy
Tel: +46 (0)10 335 1003
Email: jeanette.hedencarlsson@getinge.com

 

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

https://news.cision.com/getinge/r/getinge-completes-acquisition-of-applikon-biotechnology-b-v-,c3001246

https://mb.cision.com/Main/942/3001246/1169705.pdf

(c) 2020 Cision. All rights reserved., source Press Releases - English

All news about GETINGE AB
06/11GETINGEá : The future of health care is connected
PU
06/10Getinge Launches Torin AI Software In US
MT
06/10GETINGEá : New Torin Artificial Intelligence Solution Improves Hospital Efficien..
PU
06/04GETINGEá : An automated bioreactor solution tailored for the next generation of ..
PU
06/04GETINGEá : grows with social funding
AQ
05/25GETINGEá : Bringing science to life in the ice hockey arena
PU
05/20GETINGEá : Pregnant COVID-19 patient saved by ECMO
PU
05/12GETINGEá : A kidney transplant made Edwin's life-saving work very personal
PU
05/10GETINGEá : Helping COVID-19 patients survive in a country under pressure
PU
04/22GETINGEá : Gets FDA Clearance For Three Ventilators Systems
MT
More news
Financials
Sales 2021 27 599 M 3 207 M 3 207 M
Net income 2021 2 563 M 298 M 298 M
Net Debt 2021 4 714 M 548 M 548 M
P/E ratio 2021 33,4x
Yield 2021 0,81%
Capitalization 85 987 M 9 958 M 9 992 M
EV / Sales 2021 3,29x
EV / Sales 2022 3,08x
Nbr of Employees 10 745
Free-Float 80,0%
Chart GETINGE AB
Duration : Period :
Getinge AB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GETINGE AB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 294,55 SEK
Last Close Price 315,70 SEK
Spread / Highest target 10,9%
Spread / Average Target -6,70%
Spread / Lowest Target -38,9%
EPS Revisions
Managers and Directors
NameTitle
Mattias Sven Perjos President, Chief Executive Officer & Director
Lars Sandstr÷m Chief Financial Officer
Johan Malmquist Chairman
Anna Romberg Executive VP-Legal, Compliance & Governance
Johan Bygge Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GETINGE AB62.52%9 958
NOVOCURE LIMITED26.41%22 990
MASIMO CORPORATION-10.56%12 650
PENUMBRA, INC.52.90%9 969
SHOCKWAVE MEDICAL, INC.81.42%6 586
ASAHI INTECC CO., LTD.-30.23%6 246